OncoMatch/Clinical Trials/NCT06991101
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Is NCT06991101 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ruxolitinib and Temozolomide for glioblastoma.
Treatment: Ruxolitinib · Temozolomide — The purpose of this research is to test the safety and effectiveness of the investigational drug ruxolitinib when it is combined with standard of care treatment (radiation therapy and temozolomide) for the treatment of newly diagnosed glioblastoma. Half the people in the study will be assigned to take the study drug ruxolitinib in addition to the standard of care temozolomide and radiation therapy and the other half will be assigned to the standard of care temozolomide and radiation therapy only. This assignment will be randomized in a 1-to-1 ratio, like the flip of a coin.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Allowed: MGMT indeterminate
Allowed: MGMT methylated
Allowed: MGMT unmethylated
Prior therapy
Cannot have received: ruxolitinib (ruxolitinib)
Patient has previously taken ruxolitinib or is allergic to components of the study drug.
Cannot have received: chemotherapeutics or investigational agents for brain tumor
Patients receiving concurrent therapy for their brain tumor (e.g., chemotherapeutics or investigational agents).
Cannot have received: other chemotherapeutics or investigational agents in addition to radiation therapy and concomitant temozolomide
Patients who received other chemotherapeutics or investigational agents in addition to their radiation therapy and concomitant temozolomide treatment.
Lab requirements
Blood counts
ANC ≥ 1500/mm3 (no G-CSF within 1 week prior to screening); Platelet count ≥ 100,000/mm3 (no platelet transfusion within 1 week prior to registration)
Kidney function
Liver function
Total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; serum albumin ≥ 2.5 g/dL
Adequate organ (liver and renal) and bone marrow function within 14 days before randomization. For all parameters listed below, the most recent results available must be used: Absolute neutrophil count (ANC) ≥ 1500/mm3. Platelet count ≥ 100,000/mm3. Total bilirubin (TBL) ≤ 1.5 × institutional upper limit of normal (ULN). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × ULN. Serum albumin ≥ 2.5 g/dL.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute at Baptist Health, Inc. · Miami, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify